Antidote: Coumadin

Share this article:
I and every other clinician who treats patients with the common blood thinner warfarin (Coumadin) have a problem. The effect of the drug is delayed. If gauging the effect of the drug wasn't difficult enough by the time delay, the problem is made worse because other medications such as antibiotics cross-react and slow the metabolism of Coumadin, while foods that contain vitamin K neutralize its effects.     
As a result, managing the effects of Coumadin as a blood thinner requires frequent monitoring of blood tests, and getting it right is part of the art of medicine. Unfortunately, the number too often slips high or low, increasing the risk of either bleeding or clotting.                   
For the last few years scientists have been getting closer and closer to a suitable oral replacement. Derived from the saliva of ticks, and working by a totally different mechanism than Coumadin, studies have been ongoing on two drugs, dabigatran (Pradaxa), a direct thrombin (factor X) inhibitor which was approved by the FDA last month for blood thinning stroke patients with atrial fibrillation, and rivaroxaban (Xarelto), a factor Xa inhibitor which seems to be on the verge of approval. Both of these new drugs are patient friendly, not requiring blood tests or a special diet. The only real downside of these drugs versus warfarin is that they lack a ready antidote.
For all the negative press and publicity that occurs when a drug fails, it would be appropriate to see a media frenzy welcoming in these two great, new drugs. Don't expect it any time soon. Warfarin, take a bow, your time in the forefront is rapidly drawing to a close.
Marc Siegel, MD, is an internist and professor of medicine at New York University and the author of False Alarm: The Truth About the Epidemic of Fear
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete October 2014 Digital Edition

Read the complete October 2014 Digital Edition

Click the above link to access the complete Digital Edition of the October 2014 issue of MM&M, with all text, charts and pictures.

Predicting your pink slip

Predicting your pink slip

Any time a firm needs to save money, high-salaried executives are targets

Private View: New ways to engage with customers

Private View: New ways to engage with customers

These healthcare social media campaigns successfully use emotion, altruism and the human desire to "brand" oneself to get customers engaged.